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Objective: This study aimed to identify features on preoperative computed tomography (CT) scans that
are predictive of suboptimal primary cytoreduction and to evaluate the correlation between CT ﬁndings
and intraoperative ﬁndings in advanced ovarian cancer.
Materials and methods: We retrospectively reviewed preoperative CT scans and operative ﬁndings from
patients with stage III/IV epithelial ovarian cancer who underwent primary cytoreduction between 2003
and 2006. Fourteen criteria were assessed. Clinical data were extracted from medical records. Residual
tumors measuring 1 cm were considered suboptimal.
Results: We retrospectively identiﬁed 118 patients who met the study inclusion criteria. The rate of
optimal cytoreduction (1 cm residual disease) was 40%. On preoperative CT scans, omental extension to
the stomach or spleen and inguinal or pelvic lymph nodes >2 cm were predictors of suboptimal
cytoreduction on univariate (p ¼ 0.016 and p ¼ 0.028, respectively) and multivariate analysis (p ¼ 0.042
and p ¼ 0.029, respectively). Involvement of both omental extension and inguinal or pelvic lymph nodes
had a positive predictive value (PPV) of 100%, a speciﬁcity of 100%, and an accuracy of 45.8% in predicting
suboptimal cytoreduction. We correlated the preoperative CT ﬁndings with the intraoperative ﬁndings.
There were signiﬁcant correlations between CT and intraoperative ﬁndings of omental extension
(p ¼ 0.007), inguinal or pelvic lymph nodes >2 cm (p < 0.001), and large bowel mesentery implants
>2 cm (p ¼ 0.001).
Conclusion: The combination of omental extension to the stomach or spleen and involvement of inguinal
or pelvic lymph nodes in preoperative CT scans is considered predictive of suboptimal cytoreduction.
These patients may be more appropriately treated with neoadjuvant chemotherapy followed by surgical
cytoreduction.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction stage EOC is based on primary cytoreductive surgery followed byEpithelial ovarian cancer (EOC) has the worst prognosis among
gynecological malignancies because it is usually diagnosed in the
advanced stage of the disease [1]. The incidence increases with age
and is most prevalent in the 8th decade of life, with an incidence
rate of 57/100,000 women. The median age at the time of diagnosis
is 63 years, and 70% of patients present with advanced disease
(stage III/IV) at the time of diagnosis [2]. Treatment in advanced-s and Gynecology, Samsung
f Medicine, 50 Irwon-dong,
rk.
bstetrics & Gynecology. Publishedplatinum-based chemotherapy. The extent of residual disease after
primary cytoreductive surgery is an important predictor of prog-
nosis [3]. Although optimal cytoreduction is a highly signiﬁcant
predictor of outcome, the beneﬁt of suboptimal cytoreduction is
less evident [4]. Patients who undergo suboptimal primary cytor-
eduction may incur signiﬁcant surgical morbidity without an
associated gain in survival.
A very recent prospective, randomized study comparing upfront
debulking surgery versus neoadjuvant chemotherapy was pub-
lished. This study (EORTC 55971) demonstrated that neoadjuvant
chemotherapy followed by interval debulking surgery was not
inferior to primary debulking surgery followed by chemotherapy as
a treatment option for patients with bulky stage IIIC or IV ovarian
cancer [5].by Elsevier Taiwan LLC. All rights reserved.
Table 1
Clinical data and tumor characteristics of study patients (N ¼ 118).
Patients
No. %
Age (y)
<50 36 30
50e59 46 39
60e 69 28 24
70e79 7 6
80 1 1
ASA status
1 64 55.7
2 47 40.9
3 4 3.4
FIGO stage
III A/B 10 8
III C 100 85
IV 8 7
Histologic subtype
Serous 96 82
Transitional 11 9
Endometrioid 6 5
Mixed 5 4
Optimal cytoreduction 47 40
Suboptimal cytoreduction 71 60
CA-125 levels (U/mL)
500 33 28.7
>500 82 71.3
ASA ¼ American Society of Anesthesiologists; FIGO ¼ International Federation of
Gynecology and Obstetrics.
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stage EOC who cannot be cytoreduced optimally by primary sur-
gery may facilitate the identiﬁcation of more tailored treatment
strategies [6]. In order to increase the accuracy of preoperative
prediction, many authors have attempted to identify speciﬁc pre-
dictors of suboptimal cytoreduction. Currently available prediction
models use clinical and radiographic characteristics. A number of
studies have demonstrated an association between the preopera-
tive CA-125 level and the inability to achieve optimal cytor-
eduction; yet the overall accuracy for predicting surgical outcome
was only 50e78%, withmost studies using a CA-125 cut-off value of
500 U/mL [7e13]. The limited usefulness of using preoperative CA-
125 for triage has been documented by other studies [12,14]. Pre-
dictors of suboptimal cytoreductive surgery that can be identiﬁed
on computed tomographic (CT) scans include diaphragm disease,
diffuse peritoneal thickening, and large bowel mesentery implants
[6,10,15,16]. Interpretation of the results of studies published to
date is limited due to their retrospective nature, the highly variable
rates of optimal cytoreduction (33e80%), the fact that most studies
included patients with both early- and advanced-stage disease
[3,15,17,18], and the different combinations of CT predictors that
correlated with suboptimal cytoreduction in each of the study co-
horts; the latter calls into question the applicability of identiﬁed CT
predictors to other patient populations.
In this study, we evaluated the correlation between CT ﬁndings
and intraoperative ﬁndings prior to cytoreductive surgery, and
identiﬁed features on CT scans to predict suboptimal primary
cytoreduction in advanced ovarian cancer.
Materials and methods
Patient selection
We retrospectively reviewed electronic medical records to
identify patients with EOC who were treated at Samsung Medical
Center, Sungkyunkwan University School of Medicine, Seoul, Korea,
between January 2003 and December 2006.
A total of 239 patients with EOC were treated during this time
period. We excluded patients who were diagnosed with stage I/II
ovarian cancer (n ¼ 78), received neoadjuvant chemotherapy
(n¼ 20), or did not have preoperative CT scans within 4weeks prior
to primary cytoreductive surgery (n¼ 23). Finally,118 patients were
selected for the analysis.
All patients underwent standard abdominal midline laparot-
omy, and intensive surgical staging was attempted according to the
standard guidelines. Maximal surgical effort (achievement of no
macroscopic residual tumor or <1 cm residual disease) was
attempted in all patients, and when possible, included surgical
removal of all tumor masses, along with total abdominal hyster-
ectomy, bilateral salpingo-oophorectomy, total omentectomy, ap-
pendectomy, multiple biopsies, or additional surgery if required
[large bowel resections (5.1%), small bowel resection (1.7%), dia-
phragm stripping (2.5%), splenectomy (2.5%), and abdominopelvic
peritoneal resection (39.0%)]. Systematic pelvic and para-aortic
lymphadenectomy was performed in all patients who underwent
primary cytoreduction leaving a residual tumor of 1 cm.
Patient evaluation
Only patients who had preoperative CT scans within 4 weeks
prior to primary cytoreductive surgery and whose CT ﬁlms were
available for reviewwere included in the study. Fourteen radiologic
and surgical criteria were chosen from pertinent positive predictors
gathered from previous studies [6,10,16] and supplemented with
potential predictors from clinical experience. Radiologic criteriaincluded presence of large-volume ascites, pleural effusion, diffuse
peritoneal thickening, omental cake, omental extension to the
spleen or stomach, suprarenal lymph nodes larger than 1 cm,
infrarenal or inguinal lymph nodes larger than 1 cm, and tumor
implants larger than 2 cm on small and large bowel mesentery,
peritoneum, diaphragm, liver, or porta hepatis. Large-volume as-
cites were noted when the presence of ascites was visible on two-
thirds or more of the abdominopelvic CT scan or when more than
1 L of ascites was observed on surgical ﬁndings.
Diffuse peritoneal thickening was deﬁned as peritoneal thick-
ening to 4 mm involving at least two of the ﬁve following areas:
lateral colic gutters, lateral conal fascia, anterior abdominal wall,
diaphragm, and pelvic peritoneal reﬂections [10].
Demographic data, surgical ﬁndings, and pathologic data were
retrospectively obtained from medical records. Optimal cytor-
eduction was deﬁned as 1 cm residual disease. The clinical data
used in the analysis included age, CA-125 serum levels, and the
American Society of Anesthesiologists physical status classiﬁcation,
which were obtained from the anesthesia record. Collected labo-
ratory values included preoperative CA-125 levels obtained within
4 weeks prior to surgery.
Postoperatively, all patients received taxane/platinum combi-
nation chemotherapy for six to eight cycles. Follow-up information
was recorded until the date of last contact or death. Survival time
was calculated from the date of last chemotherapy to the date of
last contact or death. Survival outcomes were analyzed based on
the pattern of disease spread at various anatomic sites.Data analysis
Univariate comparisons between patients with optimal versus
suboptimal cytoreduction were carried out using Chi-square and
Fisher's exact tests for each of the 14 potential radiologic and oper-
ative predictors and clinical parameters. Simultaneous multivariate
analysis of all 14 radiologic and surgical variables was carried out
using backward stepwise logistic regression. After the normality of
Table 3
Univariate analysis of computed tomography predictors of suboptimal
cytoreduction.
Predictors Patients p
With variables
present
With variables
absent
No. Suboptimal No. Suboptimal
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was used for the analysis of differences, depending on the
distribution of the continuous variables. The survival curves were
calculated according to the KaplaneMeier method and compared
with the log-rank test. All p values reported are two sided, and
statistical signiﬁcance was deﬁned as p < 0.05. Statistical analysis
was performed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).(%) (%)
Diaphragm disease >2 cm 11 72.7 107 58.9 0.522
Liver implants 39 66.7 79 57.0 0.311
Porta hepatis or gallbladder
fossa disease
3 66.7 115 60.0 0.10
Diffuse peritoneal thickening 77 58.4 41 63.4 0.599
Peritoneal implants >2 cm 33 72.7 85 55.3 0.084
Large-volume ascites 77 66.2 41 48.8 0.065
Large bowel mesentery
implants >2 cm
25 76.0 93 55.9 0.069
Small bowel mesentery
implants >2 cm
13 61.5 105 60.0 0.915
Omental extension to
stomach or spleen
21 85.7 97 54.6 0.008
Omental cake 59 64.4 59 55.9 0.347
Suprarenal lymph nodes >1 cm 6 83.3 112 58.9 0.234
Infrarenal lymph nodes >1 cm 23 73.9 95 56.8 0.124
Inguinal or pelvic lymph
nodes >2 cm
23 82.6 95 54.7 0.014
Pleural effusion 33 75.8 85 54.1 0.031Results
In total, 118 consecutive patients met the study inclusion
criteria. The demographic and clinical data are presented in Table 1.
Of these patients, 93% had International Federation of Gynecology
and Obstetrics (FIGO) stage III disease, and the remaining 7% had
FIGO stage IV disease. In addition, 47 patients (40%) were optimally
cytoreduced to 1 cm residual disease at the time of primary
surgery.
There were no statistically signiﬁcant differences in median age
(optimal: 52 years; range, 24e84 years; suboptimal: 57 years;
range, 26e78; p ¼ 0.084), CA-125 levels (optimal: 852.0 U/mL;
range, 74e10,080 U/mL; suboptimal: 1296.0; range
128.6e12,350.0; p ¼ 0.082), or American Society of Anesthesiolo-
gists status [optimal (1/2/3: 61.7%/34%/4.3%) vs. suboptimal (52.1%/
45.1%/2.8%); p ¼ 0.502] between individuals who were optimally
cytoreduced and those who were suboptimally debulked. An as-
sociation was noted between both age and CA-125 level and the
proportion of patients who underwent suboptimal cytoreduction,
but this did not reach statistical signiﬁcance (p ¼ 0.084 and
p ¼ 0.082, respectively; Table 2).
Table 3 presents the percentage of patients who underwent
suboptimal debulking according to each of the 14 preoperative CT
variables. Omental extension to the stomach or spleen (p ¼ 0.016)
and inguinal or pelvic nodes (p ¼ 0.028) were the only statistically
signiﬁcant univariate predictors of suboptimal cytoreduction. Of
these 14 potential predictors, multivariate logistic analysis identi-
ﬁed only omental extension (risk ratio, 3.77; p ¼ 0.042) and
inguinal or pelvic nodes (risk ratio, 3.56; p ¼ 0.029) as signiﬁcant
predictors of suboptimal cytoreduction. In total, 85.7% of women
who were positive for omental extension to the stomach or spleen
and 82.6% of thosewith inguinal or pelvic nodes on preoperative CT
scan were suboptimally debulked. Although peritoneal implants
>2 cm and pleural effusion demonstrated borderline signiﬁcance
on univariate analysis, they lost any trend toward signiﬁcance on
multivariate analysis.
Patients with no disease on the omental extension to the
stomach or spleen and inguinal or pelvic nodes had the lowest ratesTable 2
Multivariate analysis of clinical predictive factors of suboptimal cytoreduction.
Patients (%) p
Optimal group Suboptimal group
Age, y
Median (range) 52 (24e84) 56.5 (26e78) 0.467
65 38 (84.4) 55 (78.57)
>65 7 (15.6) 15 (21.43)
CA-125, U/mL
Median (range) 852 (74e10,080) 1296 (128.6e12,350) 0.082
500 17 (37.8) 16 (22.9)
>500 28 (62.2) 54 (77.1)
ASA status 0.502
1 29 (61.7) 37 (52.1)
2 16 (34.0) 32 (45.1)
3 2 (4.3) 2 (2.8)
ASA ¼ American Society of Anesthesiologists.of suboptimal cytoreduction (50.6%). Patients with one, but not
both, of the risk factors (omental extension to the stomach or
spleen and inguinal or pelvic nodes, on preoperative CT) had in-
termediate rates of suboptimal cytoreduction (75.0e78.6%),
whereas those with both of the risk factors had the highest rates of
suboptimal cytoreduction (100%). Thus, patients with both CT
predictors were 1.98 times more likely to be suboptimally debulked
than those with neither predictor (Table 4).
We correlated the CT ﬁndings with the intraoperative ﬁndings.
There were signiﬁcant correlations between CT and intraoperative
ﬁndings in liver implants, large-volume ascites, omental cake,
omental extension, infrarenal lymph nodes >1 cm, inguinal or
pelvic nodes, and large bowel mesentery implants >2 cm (Table 5).
Finally, we analyzed the inﬂuence of statistically signiﬁcant
predictors on survival. Inguinal or pelvic nodes and peritoneal
implants >2 cm on CT scans showed a negative association with
progression-free survival (p ¼ 0.07 and p ¼ 0.043, respectively;
Fig. 1).Discussion
In this retrospective study, we observed that omental extension
to the stomach or spleen and inguinal canal disease or pelvic lymph
nodes on preoperative CT scans are the only statistically signiﬁcant
predictors of suboptimal cytoreduction. Furthermore, those pre-
dictors were correlated with intraoperative ﬁndings, and inguinalTable 4
Multivariate risk factors for suboptimal cytoreduction.
Omental extension Inguinal canal
disease or pelvic LN
Suboptimal Risk ratioa
No. %
No No 41/81 50.6 1
No Yes 12/16 75.0 1.48
Yes No 11/14 78.6 1.55
Yes Yes 7 100 1.98
LN ¼ lymph node.
a Using absence of omental extension and inguinal canal disease as the reference.
Table 5
Correlation between CT scan ﬁndings and intraoperative ﬁndings.
Predictors No. of patients with predictor
CT
scan
Intraoperative Correlation, p
Diaphragm disease >2 cm 11 7 0.128
Liver implants 39 43 0.019
Porta hepatis or gallbladder fossa disease 3 3 0.075
Peritoneal implants >2 cm 33 63 0.304
Large-volume ascites 77 82 <0.001
Large bowel mesentery implants >2 cm 25 42 0.001
Small bowel mesentery implants >2 cm 13 48 NS
Omental extension to stomach or spleen 21 43 0.007
Omental cake 59 86 <0.001
Suprarenal lymph nodes >1 cm 6 1 NS
Infrarenal lymph nodes >1 cm 23 13 0.004
Inguinal or pelvic lymph nodes >2 cm 23 20 <0.001
CT ¼ computed tomography; NS ¼ not signiﬁcant.
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free survival.
Those with both omental extension to the stomach or spleen
and inguinal canal disease on preoperative CT had the highest rates
of suboptimal cytoreduction, and these two variables combined
had a PPV and speciﬁcity of 100%. It is very important to achieve the
highest degree of accuracy possible, in order tominimize the rate of
cases erroneously judged to have unresectable disease. This goal is
more relevant than running the risk of unnecessarily exploring
patients who present with unresectable disease at laparotomy. The
results of our study indicate that the presence of both predictors on
CT scan can decrease the rate of inappropriate exploratory lapa-
rotomy to 0%. This study shows that parameters assessed by CT scan
may conceivably offer predictive value, as they deﬁne not only the
extent of disease, but more importantly, the involvement of speciﬁc
intra-abdominal sites that are generally recognized to heavily
preclude the feasibility of optimal debulking.
Despite the statistical signiﬁcance, the clinical relevance of those
CT predictors remains questionable, because the current study
comprised a limited patient population. Several investigators have
retrospectively tried to specify preoperative CT predictors of sub-
optimal cytoreduction in stage III/IV patients [6,10,16]. The previ-
ously known predictors have been different for each cohort ofFig. 1. Progression-free survival curves of patients according to computed tomography-
implants >2 cm.investigated patients, and they have shown a lack of generaliz-
ability when applied to other cohorts of patients [6]. One of the
principal difﬁculties in the development of any reliable predictive
model of surgical outcome for patients with advanced ovarian
cancers is the challenge of including the signiﬁcant impact of each
individual surgeon's philosophy, effort, and ability to utilize
advanced surgical techniques to achieve maximal cytoreduction
[18].
There were some limitations to this study. First, this was a
retrospective analysis of a single-center cohort of patients with
advanced ovarian cancer. The most important predictors vary be-
tween institutions depending on surgical practice and cytor-
eduction rates, so our results may not be applicable to other
institutions and surgeons. As evidenced by a review of all published
CT predictor data to date, each of the retrospective studies
[10,15e18], including the present study, identiﬁed a different set of
predictors of cytoreductive surgery outcome, which calls into
question the general applicability of these predictors.
Second, although it can be argued that the percentage of optimal
cytoreduction in our series was far from the upper limit of the range
reported in the literature [19], our results must be interpreted
taking into account the fact that our patients were selected on the
basis of clinical and radiographic features of very advanced disease,
thus resulting in 92% FIGO stage IIIC/IV cases; by contrast, other
series also included FIGO stage I/II patients, in a range between 19%
and 45% [15,17,18,20,21]. Moreover, it should be acknowledged that
a very high percentage of optimal cytoreductions are hardly
achievable outside a few very committed institutions. In this
context, the availability of a tool suitable to adapt to the range of the
most commonly achievable rates of optimal cytoreduction is clin-
ically relevant [22].
Finally, we deﬁned the optimal cytoreduction as residual lesions
of 1 cm, which does not differ from that reported in previous
studies [10,15,16,18]. Today, the generally accepted deﬁnition of
optimal cytoreduction is a residual tumor diameter no greater than
1 cm. However, resection of all macroscopic disease is the goal of
cytoreductive surgery and is associated with the best survival [23].
Thus, an ideal standard for a validation study would be complete
removal of visible residual disease as an endpoint.
We chose 14 radiologic criteria from pertinent positive pre-
dictors gathered from previous studies [6,10,16], and a model usingbased predictors in patients with (A) inguinal or pelvic nodes and (B) peritoneal
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optimal cytoreduction.
In conclusion, we have demonstrated that CT scan is a valid tool
for the preoperative prediction of successful resection of ovarian
cancer during primary surgery. However, the CT-based risk factors
for suboptimal cytoreduction identiﬁed in our study differed from
the factors identiﬁed in previously published cohorts. Although we
did not perform cross-validation of the model in other cohorts, this
result conﬁrms that identiﬁcation of CT-based risk factors for sub-
optimal cytoreduction in small retrospective populations is not
reproducible in alternate populations [6]. Dowdy et al [10]
emphasized that resectability is a relative term. They also sug-
gested that studies demonstrating the value of speciﬁc predict-
ability criteria need to be interpreted with extreme caution because
the reproducibility of ﬁndings is likely to be dependent on a similar
practice pattern and anticipated optimal debulking rates.
Ultimately, a multi-institutional prospective trial would deter-
mine whether or not an accurate and reproducible preoperative
model using CT or other imaging modalities could be developed for
the prediction of surgical outcome.
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